Provided by Tiger Trade Technology Pte. Ltd.

Neurocrine Biosciences

154.03
-0.0300-0.02%
Pre-market: 154.030.00000.00%07:03 EDT
Volume:1.74M
Turnover:267.98M
Market Cap:15.71B
PE:22.58
High:155.00
Open:153.11
Low:151.77
Close:154.06
52wk High:186.12
52wk Low:122.14
Shares:102.00M
Float Shares:100.00M
Volume Ratio:1.77
T/O Rate:1.74%
Dividend:- -
Dividend Rate:- -
EPS(TTM):6.82
EPS(LYR):4.67
ROE:22.09%
ROA:11.70%
PB:4.25
PE(LYR):32.98

Loading ...

Neurocrine Biosciences (NBIX) Cleared An FDA Milestone, Is It Trading At A Discount?

Simply Wall St.
·
Aug 29

How Investors May Respond To Neurocrine Biosciences (NBIX) Phase 4 INGREZZA Patient-Reported Benefit Data

Simply Wall St.
·
Aug 27

Nxera Pharma Says Neurocrine Wins FDA IND Clearance for Phase 2 Alzheimer’s Cognition Trial of NBI-1117567

Reuters
·
Aug 26

Nxera Pharma Co., Ltd.: Milestone Payment is Expected to be Recognised in Full as Revenue in Q3 Fy2026

THOMSON REUTERS
·
Aug 26

Nxera Pharma Co., Ltd.: Nxera Pharma's Partner Neurocrine Biosciences Receives Ind Acceptance from FDA for Phase 2 Study of Nbi-1117567 for Alzheimer's Cognition

THOMSON REUTERS
·
Aug 26

Nxera Pharma Co., Ltd.: Partner Neurocrine Biosciences Received Ind Acceptance from U.S. Food and Drug Administration (FDA) for a Phase 2 Study of Nbi-1117567 for Alzheimer's Cognition

THOMSON REUTERS
·
Aug 26

S&P 500 Futures up in Premarket Trading; Dick's Sporting Goods, Ameris Bancorp Lag

Dow Jones
·
Aug 25

Neurocrine Biosciences (NBIX) Stock Still Looks Like A Bargain Following Its 59% Run

Simply Wall St.
·
Aug 25

Neurocrine Biosciences (NBIX) Could Be 28% Undervalued On Fresh INGREZZA Data

Simply Wall St.
·
Aug 18

Rhythm Pharmaceuticals Appoints Manher “AJ” Joshi as Chief Medical Officer

Reuters
·
Aug 17

Neurocrine price target lowered to $182 from $196 at Morgan Stanley

TIPRANKS
·
Aug 17

Neurocrine Price Target Cut to $182.00/Share from $196.00 by Morgan Stanley

Dow Jones
·
Aug 13

Analysts’ Top Healthcare Picks: Neurocrine (NBIX), Aquestive Therapeutics (AQST)

TIPRANKS
·
Aug 13

Deutsche Bank Adjusts Neurocrine Biosciences PT to $165 From $190, Maintains Hold Rating

MT Newswires Live
·
Aug 13

Neurocrine Biosciences, Inc. : Deutsche Bank Cuts Target Price to $165 from $190

THOMSON REUTERS
·
Aug 13

Deutsche Bank Sticks to Its Hold Rating for Neurocrine (NBIX)

TIPRANKS
·
Aug 13

U.S. Stocks on the MOVE-Sutro Biopharma, Humacyte

Reuters
·
Aug 13

Global Markets Steady as AI Optimism Returns, Focus Shifts to US Inflation Data

Deep News
·
Aug 12

Neurocrine Biosciences Announces Publication of Kinect-Pro™ Findings Demonstrating Ingrezza® (Valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia

THOMSON REUTERS
·
Aug 12

Prader-Willi Groups Cite Deaths Tied to Neurocrine's Genetic Disorder Drug, Shares Fall

Reuters
·
Aug 12